中国临床药学杂志

参考文献

[1] GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050:a systematic analysis for the Global Burden of Disease study 2021[J]. Lancet, 2023, 402(10397):203.

[2] XU Y, LU J L, LI M, et al. Diabetes in China part 1:epidemiology and risk factors[J]. Lancet Public Health, 2024, 9(12):e1089.

[3] KE C, VENKAT NARAYAN K M, CHAN J C N, et al.Pathophysiology, phenotypes and management of type 2 diabetes mellitus inIndian and Chinese populations[J]. NatRev Endocrinol, 2022, 18(7):413.

[4] LI Y P, WANG D D, LEY S H, et al. Time trends of dietary and lifestyle factors and their potential impact on diabetes burden in China[J]. Diabetes Care, 2017, 40(12):1685.

[5] SUN X M, YAN A F, SHI Z M, et al. Health consequences of obesity and projected future obesity health burden in China[J].Obesity(Silver Spring), 2022, 30(9):1724.

[6] LUO D M, MA N, LIU Y F, et al. Long-term trends and urbanrural disparities in the physical growth of children and adolescents in China:an analysis of five national school surveys over three decades[J]. Lancet Child Adolesc Health, 2023, 7(11):762.

[7] YUAN C Z, DONG Y H, CHEN H, et al. Determinants of childhood obesity in China[J]. Lancet Public Health, 2024,9(12):e1105.

[8] FORZANO I, VARZIDEH F, AVVISATO R, et al. Tirzepatide:a systematic update[J]. Int J Mol Sci, 2022, 23(23):14631.

[9] COSKUN T, SLOOP K W, LOGHIN C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2diabetes mellitus:from discovery to clinical proof of concept[J].Mol Metab, 2018, 18:3.

[10] GALLWITZ B. Clinical perspectives on the use of the GIP/GLP-1receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity[J]. Front Endocrinol(Lausanne), 2022, 13:1004044.

[11] SCHNECK K, URVA S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide[J]. CPT Pharmacometrics Syst Pharmacol, 2024, 13(3):494.

[12] MARTIN J A, CZESKIS B, URVA S, et al. Absorption, distribution,metabolism, and excretion of tirzepatide in humans, rats, and monkeys[J]. Eur J Pharm Sci, 2024, 202:106895.

[13] FURIHATA K, MIMURA H, URVA S, et al. A phase 1 multipleascending dose study of tirzepatide in Japanese participants with type 2 diabetes[J]. Diabetes Obes Metab, 2022, 24(2):239.

[14] URVA S, QUINLAN T, LANDRY J, et al. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1receptor agonist tirzepatide[J]. Clin Pharmacokinet, 2021, 60(8):1049.

[15] URVA S, QUINLAN T, LANDRY J, et al. Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1receptor agonist tirzepatide[J]. Clin Pharmacokinet, 2022, 61(7):1057.

[16] MULLINS G R, HODSDON M E, LI Y G, et al. Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety:analysis of data from phase 3 studies[J]. J Clin Endocrinol Metab, 2024,109(2):361.

[17] RHEA E M, BABIN A, THOMAS P, et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases[J]. Tissue Barriers, 2024, 12(4):2292461.

[18] GUAN R F, LI X N, MA G. Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling[J]. Front Pharmacol, 2023, 14:1326373.

[19] NAUCK M A, D’ALESSIO D A. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction[J]. Cardiovasc Diabetol, 2022, 21(1):169.

[20] CORRAO S, POLLICINO C, MAGGIO D, et al. Tirzepatide against obesity and insulin-resistance:pathophysiological aspects and clinical evidence[J]. Front Endocrinol(Lausanne), 2024, 15:1402583.

[21] CAMPBELL J E, MüLLER T D, FINAN B, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry,physiology, and clinical applications[J]. Cell Metab, 2023, 35(9):1519.

[22] GASBJERG L S, BERGMANN N C, STENSEN S, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists[J]. Peptides, 2020, 125:170183.

[23] MAYENDRARAJ A, ROSENKILDE M M, GASBJERG L S. GLP-1 and GIP receptor signaling in beta cells-a review of receptor interactions and co-stimulation[J]. Peptides, 2022, 151:170749.

[24] HEISE T, MARI A, DEVRIES J H, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes:a multicentre,randomised, double-blind, parallel-arm, phase 1 clinical trial[J].Lancet Diabetes Endocrinol, 2022, 10(6):418.

[25] ROSENSTOCK J, WYSHAM C, FRíAS J P, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes(SURPASS-1):a double-blind,randomised, phase 3 trial[J]. Lancet, 2021, 398(10295):143.

[26] FRíAS J P, DAVIES M J, ROSENSTOCK J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6):503.

[27] LUDVIK B, GIORGINO F, JóDAR E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type2 diabetes(SURPASS-3):a randomised, open-label, parallel-group,phase 3 trial[J]. Lancet, 2021, 398(10300):583.

[28] GASTALDELLI A, CUSI K, FERNANDEZ LANDóL, et al.Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes(SURPASS-3MRI):a substudy of the randomised, open-label, parallel-group,phase 3 SURPASS-3 trial[J]. Lancet Diabetes Endocrinol, 2022,10(6):393.

[29] DEL PRATO S, KAHN S E, PAVO I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk(SURPASS-4):a randomised, open-label, parallel-group,multicentre, phase 3 trial[J]. Lancet, 2021, 398(10313):1811.

[30] DAHL D, ONISHI Y, NORWOOD P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes:the SURPASS-5 randomized clinical trial[J]. JAMA, 2022, 327(6):534.

[31] ROSENSTOCK J, FRíAS J P, RODBARD H W, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes:the SURPASS-6 randomized clinical trial[J]. JAMA, 2023, 330(17):1631.

[32] KADOWAKI T, CHIN R, OZEKI A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan(SURPASS J-combo):a multicentre, randomised, open-label, parallel-group,phase 3 trial[J]. Lancet Diabetes Endocrinol, 2022, 10(9):634.

[33] INAGAKI N, TAKEUCHI M, OURA T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes(SURPASS J-mono):a double-blind,multicentre, randomised, phase 3 trial[J]. Lancet Diabetes Endocrinol, 2022, 10(9):623.

[34] GAO L L, LEE B W, CHAWLA M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region:the SURPASS-AP-Combo trial[J]. Nat Med,2023, 29(6):1500.

[35] YAO H Q, ZHANG A Q, LI D L, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes:systematic review and network meta-analysis[J]. BMJ, 2024, 384:e076410.

[36] JASTREBOFF A M, ARONNE L J, AHMAD N N, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022,387(3):205.

[37] TIMOTHY GARVEY W, FRIAS J P, JASTREBOFF A M, et al.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes(SURMOUNT-2):a double-blind, randomised,multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2023,402(10402):613.

[38] WADDEN T A, CHAO A M, MACHINENI S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity:the SURMOUNT-3 phase 3 trial[J]. Nat Med, 2023, 29(11):2909.

[39] ARONNE L J, SATTAR N, HORN D B, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity:the SURMOUNT-4 randomized clinical trial[J]. JAMA,2024, 331(1):38.

[40] ARONNE L J, HORN D B, LE ROUX C W, et al. Tirzepatide as compared with semaglutide for the treatment of obesity[J]. N Engl J Med, 2025, 393:26.

[41] ZHAO L, CHENG Z F, LU Y B, et al. Tirzepatide for weight reduction in Chinese adults with obesity:the SURMOUNT-CN randomized clinical trial[J]. JAMA, 2024, 332(7):551.

[42] MALHOTRA A, GRUNSTEIN R R, FIETZE I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity[J]. N Engl J Med, 2024, 391(13):1193.

[43] LOOMBA R, HARTMAN M L, LAWITZ E J, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024, 391(4):299.

[44] ARVANITAKIS K, KOUFAKIS T, KALOPITAS G, et al.Management of type 2 diabetes in patients with compensated liver cirrhosis:short of evidence, plenty of potential[J]. Diabetes Metab Syndr Clin Res Rev, 2024, 18(1):102935.

[45] TARGHER G. Tirzepatide adds hepatoprotection to its armoury[J].Lancet Diabetes Endocrinol, 2022, 10(6):374.

[46] KANBAY M, COPUR S, SIRIOPOL D, et al. Effect of tirzepatide on blood pressure and lipids:a meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2023, 25(12):3766.

[47] HEERSPINK H J L, SATTAR N, PAVO I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2diabetes in the SURPASS-4 trial:post-hoc analysis of an openlabel, randomised, phase 3 trial[J]. Lancet Diabetes Endocrinol,2022, 10(11):774.

[48] GUDZUNE K A, KUSHNER R F. Medications for obesity:a review[J]. JAMA, 2024, 332(7):571.

[49] DRUCKER D J. Efficacy and safety of GLP-1 medicines for type 2diabetes and obesity[J]. Diabetes Care, 2024, 47(11):1873.

[50] ZENG Q Y, XU J, MU X Y, et al. Safety issues of tirzepatide(pancreatitis and gallbladder or biliary disease)in type 2 diabetes and obesity:a systematic review and meta-analysis[J]. Front Endocrinol(Lausanne), 2023, 14:1214334.

[51] SATTAR N, MCGUIRE D K, PAVO I, et al. Tirzepatide cardiovascular event risk assessment:a pre-specified meta-analysis[J]. Nat Med, 2022, 28(3):591.

[52] POPOVIC D S, PATOULIAS D, POPOVIC L S, et al. Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus:a meta-analysis of randomized controlled trials[J].Diabetes Res Clin Pract, 2024, 213:111758.

[53] LU J M, LIU H, ZHOU Q T, et al. A potentially serious adverse effect of GLP-1 receptor agonists[J]. Acta Pharm Sin B, 2023,13(5):2291.

[54] FAILLIE J L, YIN H, YU O H Y, et al. Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes[J]. Clin Pharmacol Ther, 2022, 111(1):272.